Purpose: To comprehensively evaluate the adverse events (AEs) significantly associated with brivaracetam (BRV) treatment in a large selection of randomized control trials. Methods: We conducted an online database search using Pubmed, Embase, Cochrane Online Library, and Clinicaltrial.gov for all available randomized control trials (RCTs) that investigated the therapeutic effects of brivaracetam. Serious AEs (SAEs), withdrawal, and treatment-emergent adverse effects were then assessed for their association with brivaracetam. Finally, a meta-analysis was performed using Review Manager 5.3 software. Results: Eight RCTs with a total of 2505 patients were included in our study, 1178 of which were randomized with respect to brivaracetam (BRV). Serious AEs, overall withdrawal, AE-related withdrawal and psychiatric adverse events (PAEs) were not significantly associated with BRV treatment. BRV was also not significantly associated with a heightened risk of AE-related withdrawal and PAEs with increasing doses. Of the 17 AEs included in our meta-analysis, three AEs (dizziness, fatigue, and back pain) were found to be significantly associated with BRV treatment. But we did not find that the risk of them was obviously increasing with the increasing doses. Conclusion: This meta-analysis showed that BRV treatment was reasonably tolerated by patients and rarely caused serious AEs. Further clinical studies will be needed to more concretely determine the safety and tolerability profile of BRV.
Introduction
Epilepsy is typically characterized by recurrent and unprovoked seizures [1] . According to the WHO, approximately 50 million people throughout the world have epilepsy [2] . Despite the recent introduction of some new antiepileptic drugs (AEDs), many patients remain inadequately treated. This insufficient treatment may be due to lack of access to appropriate treatment, noncompliance, adverse effects, lack of efficacy of treatment and so on. To this end, up to 30% patients ultimately develop refractory epilepsy [3] . Therefore, there is a great therapeutic need to explore new AEDs that have both improved efficacy and a better tolerability profile.
Brivaracetam {(2S)-2-[(4R)-2-oxo-4-propylpyrrolidinyl] butanamide} is a novel AED that is currently being investigated for the treatment of epilepsy. Two Phase IIb studies (NCT00175929 and NCT00175825) and four Phase III studies (NCT00490035, NCT00504881, NCT00464269 and NCT0216358) have shown that BRV may be efficacious and well-tolerated as an adjunctive treatment in patients with refractory epilepsy. BRV displays an approximately 10-fold higher affinity than levetiracetam (LEV) for binding to synaptic vesicle protein 2A [4] . BRV also inhibits voltage-dependent sodium currents [5] and reverses the inhibitory effects of negative modulators on gamma-amino-butyric-acid (GABA) and glycine induced currents [6] . However, inhibition ofexcitatory neurotransmission may result in dysfunction in some areas of the central nervous system associated with cognitive and/or motor function impairment [7] . Considering the potential adverse events of BRV, it is necessary to first exhaustively examine the current clinical studies literature and identify adverse events (AEs) that are significantly associated with brivaracetam treatment.
Methods
According to PRISMA principles, the search strategy, selection of study, data extraction and data analysis were pre-designed but were not registered on any website [8] .
Data sources and search
We searched online databases including Pubmed, Embase, and Cochrane Online Library with no language limitations. The words we used in this search included: brivaracetam, UCB34714 and butanamide. We also searched Clinical trial.gov (https://www. clinicaltrial.gov/) for unpublished trials. Two reviewers independently reviewed the titles and abstracts from the search results for any article that was potentially relevant studies. Published trials without articles were also evaluated based on the summary of information online.
Selection of studies
The two reviewers independently assessed the eligibility of potentially relevant studies according to the predefined inclusion and exclusion criteria. Disagreements were resolved by consensus between investigators.
Inclusion criteria:
1. Study design: randomized, double-blind, placebo-controlled trials; subject contents !50. 2. Population: adults aged 16-80 years; the included subjects diagnosed with different neurological disorders. 3. Intervention: brivaracetam was used at different dosages; no restriction was imposed on the route of administration. 4. Outcomes: all data must come from full journal publications or summary of clinical trial reports; at least one of the following data must be provided by the included studies: serious AEs, withdrawal, and/or treatment-emergent adverse effects.
Exclusion criteria:
1. Study design: design of trial is not double-blind, placebocontrolled or non-RCTs; subject contents <50. 2. Population: studies in which subjects already took brivaracetam before the baseline period were excluded. 3. Outcome: the integrity of data was not ensured or over 15% of the included patients were lost in the follow up period.
Data extraction and evaluation of evidence
The two reviewers independently extracted relevant information from each eligible study using a data extraction form, which included the first author, study design, inclusion criteria of patients, dose of BRV, number of patients (intent-to-treat, ITT), percentage of patients using BRV, percentage of males, age, duration of epilepsy, titration, percent of baseline 1-2 concomitant AEDs, the kind of concomitant AEDs, seizure-free rate, number of any AEs and seizure types. The bias of included studies was assessed using the guideline for assessing risk of bias in the Cochrane handbook 5.1.0 [9] . The quality score for each study was evaluated according to Jadad score [10] , which included the domains of randomization, allocation concealment, blinding, and an explanation of withdrawal or loss to follow-up. The studies were considered as high quality if the score !4 and low quality if the score <4. Any discrepancies were resolved by consensus between investigators.
Outcome measure
Serious AEs, study withdrawals due to AEs and treatmentemergent adverse effects were investigated for measuring the adverse event profile of BRV. AEs were categorized as serious (SAEs) if they were life-threatening, resulted in death, a persistent or significant disability, a congenital birth defect, or needed inpatient hospitalization.
Data analyses
Revman 5.3 software was applied to perform meta-analysis for data processing [11] . For dichotomous variables, we calculated the risk ratios (RR) and 95% confidence intervals (95% CI) to demonstrate pooled effects using the Mantel-Haenszel method. For continuous variables, we used a reversed variance method and calculated the mean difference [12] . Fixed-effect models weight the studies by the amount of available information whereas the random-effects model accounts for between-study heterogeneity in the weighting of each study. Heterogeneity between studies was assessed using the I-squared statistic (I 2 ). I 2 values of 25% indicate low heterogeneity, values of 50% suggest moderate heterogeneity, and values of 75% suggest high levels of heterogeneity [13] . Intentto-treat population was applied for all included studies where anyone who qualified for the baseline period was considered to be involved. Sensitivity test was performed by switching statistical values and removing low-quality studies or study of high heterogeneity compared to others.
Results

Study selection
Clinical trials databases were searched for RCTs that used BRV treatment and had been published up to March 2016. This search yielded 92 papers in Pubmed, 264 in EMBASE, 66 in MEDLINE, and 28 in clinicaltrial.gov. From our initial screening, we excluded nonrandomized, placebo-controlled trials as well as studies performed on healthy volunteers. After exclusion criteria were applied, seven papers were identified, reporting on eight RCTs (two RCTs were reported in one study [20] ). A flowchart detailing the study selection process is shown in Fig. 1. 
Characters of included studies
The seven selected studies included a total of 2505 patients, 1787 of whom were randomized to a brivaracetam treatment group and 718 to placebo. Of the eight RCTs, five featured brivaracetam that had been administered to drug-resistant partialonset seizures [14, 15, [17] [18] [19] , one where brivaracetam had been administered for uncontrolled focal and generalized epilepsies [16] , and two [20] that had administered brivaracetam for treatment of Unverricht-Lundborg disease (EPM1). In all studies, drug was administered twice a day. In all but one of the studies [20] , data were obtained from fixed-dose trials. The remaining study [20] featured a flexible-dose trial. Patients from the selected studies were from a wide age range, with either drug-resistant partial epilepsy [14] [15] [16] [17] [18] [19] or generalized epilepsy [16] . But in one study, eligible patients had genetically ascertained EPM1 [20] . Brivaracetam was used as an add-on antiepileptic drugs in all studies. Patients included in four of the eight studies [14, 16, 20] underwent an up-titration period of increasing brivaracetam doses until the final dose was reached. All other included studies did not have this up-titration period [15, [17] [18] [19] . Study duration ranged from between 7 and 16 weeks. Study and patient characteristics of the included studies are shown in Table 1 .
Risk of bias
According to the Cochrane Handbook of Systematic Review, random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data and selective reporting are involved, which were showed in Table 2 . We rated all included trials as high quality because of each Jadad score !4.
Statistical analysis
All the outcomes of interest (i.e. SAEs, withdrawal, TEAEs) were dichotomous. Risk ratios (RRs) were calculated for all the outcomes. Study [NCT00504881] was designed to a flexible-dose trial, while the other included studies were designed to fixed-dose trials. And the selected studies had a wide dose range from 5 mg to 200 mg. Besides, eligible patients had genetically ascertained EPM1 in one study [20] , which was different from the others. It may be not appropriate to use the fixed-effect model which makes the assumption that the treatment effects in all the included studies are identical [21] . Therefore, the random effects model was chosen. Subgroup analyses were also conducted to detect the difference in various drug doses.
Patients with serious adverse events
Serious adverse events (SAEs) were reported in all trials. The number of serious AEs was 73/1787 (4.1%) for subjects randomized to brivaracetam treatment groups and 38/718 (5.3%) for subjects randomized to placebo. There was no significant difference in serious AEs between the brivaracetam and placebo treatment groups [RR 95% CI, 0.74 (0.50, 1.10); P = 0.13] (Fig. 2) .
Withdrawal
We found there was no significant difference in the overall withdrawal rate between the BRV and placebo groups [RR 95% CI, (Fig. 3) .AE-related withdrawal was also not associated with BRV treatment [RR 95% CI, 1.36 (0.91, 2.04); P = 0.14] (Fig. 4) . We then analyzed AE-related withdrawal in different dosage subgroups. Regardless of increasing dose, brivaracetam was not significantly associated with an increased risk of AE-related withdrawal (Fig. 5) .
Adverse events identified in the included studies
Thirty-three AEs occurred during brivaracetam treatment in our analysis. Fifteen AEs (disturbance in attention, myoclonus, abdominal pain, grand mal conclusion, tremor, balance disorder, constipation, feeling cold, appendicitis, fall, hyporeflexia, middle insomnia, otitis externa, pyrexia, upper abdominal pain) were reported in no more than five subjects among those receiving brivaracetam treatment. These AEs were considered to be rare and excluded in our analysis. We considered one AE (aggression) to be synonym with another (irritability); thus, it was merged with its corresponding AE in our analyses. The 17 remaining AEs were included in our meta-analysis. Psychiatric adverse events (PAEs) were also included in our meta-analysis.
3.4.3.1. Treatment-emergent adverse effects associated with brivaracetam. Table 3 shows all RR values (95% CI) for the 17 Table 3 ). This comparison also confirms that PAEs were not likely to be related to dosage of brivaracetam (Table 4) .
Sensitivity test
We conducted a two-part sensitivity test on our results. The first part changed the statistical value to an odds ratio. No significant changes were observed as shown in Table 5 . In the second part, we removed NCT00504881 from the analysis, which was different from the other seven trials in its experimental design. The results are shown in Table 5 . 
Discussion
In our study, eight high-quality RCTs were identified for inclusion in our meta-analysis. Our study synthesized these existing data and focused on BRV-induced adverse events such as SAEs, withdrawal and treatment-emergent adverse effects. Three previous meta-analyses evaluated the clinical efficacy and safety of BRV and suggested it had both significant effects and tolerability in patients with refractory partial seizures [22] [23] [24] . However, these studies were limited to a specific disorder and only assessed the most commonly reported treatment-emergent adverse effects (TEAEs) associated with BRV, resulting in a reduced statistical power of analysis.
In this meta-analysis, we found no significant differences in SAEs between the brivaracetam and placebo treatment groups. In these studies, SAEs were predominantly related to epilepsy (convulsion or status epilepticus) or fractures, and also included other conditions such as pneumonia, septicemia, and so on.
A good tolerability profile of BRV also emerged from the analysis of overall withdrawal, which showed no significant differences between BRV treatment (8.8%) and placebo (7.1%). Almost all patients' withdrawal was due to AEs or lacking of efficiency. Furthermore, there was no significant difference between BRV treatment and placebo in AE-related withdrawal. The most commonly reported treatment-emergent AE leading to discontinuation was psychiatric adverse events (PAEs). Phase III studies [15] [16] [17] 19, 20] have detailed accounts of PAEs, which have predominantly featured aggression, anxiety, irritability, depression, and insomnia. In our subsequent PAE meta-analysis, we found no significant difference between BRV treatment and placebo. Nonpsychotic behavioral AEs are a subgroup of psychiatric disorders that have been previously reported for levetiracetam (e.g. irritability and aggression) and appeared to be reported to a lesser extent in the present study of BRV [15] . However, there are no head-to-head studies that can confirm this observation; although a post hoc analysis of nonpsychotic behavioral TEAEs in LEV and BRV trials support this conclusion [25] . Moreover, brivaracetam was also not significantly associated with a heightened risk of AE-related withdrawal with increasing doses, as shown in our subsequent subgroup dose analysis.
Overall, 17 AEs were included in our study. Three AEs (dizziness, fatigue, and back pain) were found to be significantly associated with BRV treatment. This result was similar to those found in another study [26] , which showed the most commonly reported adverse effects with BRV treatment in adults were related to the central nervous system and included dizziness, fatigue and somnolence. Our study also showed a significant effect between BRV treatment and placebo in back pain (P = 0.03). Since only two studies [14, 16] have previously reported back pain and our subgroup analysis did not show a significant association with BRV at different doses, it is necessary to identify whether it is related to BRV treatment for further study. When we conducted a subgroup analysis of these various adverse events to evaluate the impact of different drug dosages, it remained unclear whether the adverse events of BRV treatment increased with increasing doses. However, patients receiving 200 mg/d BRV had significantly higher incidences of dizziness and fatigue. And the risk of fatigue may increase with the increasing doses. Therefore, further research is needed to allow for an in-depth understanding of the dosagerelated feature of this new AED.
The overall incidence of psychiatric TEAEs was similar for all the BRV doseages versus PBO and BRV was not significantly associated with a higher risk of PAEs with the increasing doses. The suicidal ideation was mentioned in one study [19] , in which the incidence of suicidal ideation was low and equal for PBO (one patient) and BRV overall (two patient).
In the sensitivity test, we found that our statistical methods were reliable, which provided relatively compelling results on SAEs, withdrawal, and treatment-emergent adverse effects associated with BRV. We did not find significant changes. But the adverse effects, dizziness and back pain were not associated with BRV after removing NCT00504881, which demonstrated a relatively good tolerability profile of BRV from the negative. Convulsion was associated with BRV after removing NCT00504881, considering only 4 studied included in convulsion, which may need further research to explore. These tests suggested that the NCT00504881 possibly leads to a high sensitivity and unreliable result, and further studies are needed to confirm these results.
Despite our findings, there are still some limitations in our analysis. Firstly, the RCTs included in this meta-analysis was relatively small, which may neglect rare, but severe AEs. As is known, there were two RCTs performed on healthy volunteers, which do not meet our inclusion criteria, therefore, they were excluded from our study. However, apart from these AEs included in our article, these two articles involved some other AE profile (Euphoric mood, Hypotension, Feeling drunk, Blurred version, Disturblence of attention); Secondly, adverse effects such as vertigo, upper respiratory tract infection, and neutropenia were only mentioned in one of the included studies, which might not be representative. Third, NCT00504881 was different from the other seven trials in its experimental design, which may lead to a high heterogeneity. And the data obtained from this flexible-dose trial could be only analyzed in the group regardless of dose. Finally, BRV was evaluated as an add-on treatment in the RCTs that were included in our analysis, which ranged in duration from 7 to 16 weeks. Since these were relatively short-term trials, it is possible that some adverse reactions were not observed. In addition, the treatment period and the kind of concomitant AEDs varied among the different studies. All of these factors may have affected the accuracy of the results of our analysis.
Conclusion
In conclusion, the results of this meta-analysis indicate that the use of BRV was reasonably tolerated by patients. These adverse effects ranged from mild to moderate and the tolerability profile was so excellent that it does not impair therapeutic compliance. However, due to the limitations of this analysis, our findings warrant further study to confirm the future therapeutic use of brivaracetam.
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